Immatics agreed to sell 12,945,916 ordinary shares at $8.69, plus pre-funded warrants for 4,315,304 shares, for expected gross proceeds of $150 million. Its 2025 net loss was €196.4 million, after net income of €15.2 million in 2024.
Latest Immatics news
We have not published a story on Immatics yet. When there is news, it will appear here.
Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents €345.9 million, plus short-term investments of €123.4 million, €469.3 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Immatics
Has Immatics raised money recently?
Our latest story on this, dated Aug 26, 2026: "Immatics agrees to sell shares and warrants at $8.69 in $150 million offering". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Immatics?
Immatics N.V. trades under the ticker IMTX on NASDAQ.
Where is Immatics listed?
Immatics N.V. is listed on NASDAQ. Our directory also records these other listings: DUS:4A3; FWB:4A3; GETTEX:4A3; HAM:4A3; HAN:4A3; LS:A2P72S; LSX:A2P72S; MUN:4A3; SWB:4A3; TRADEGATE:4A3; XETR:4A3.
What is the SEC CIK of Immatics?
The SEC Central Index Key (CIK) for Immatics N.V. is 1809196. Its filings are on SEC EDGAR.
How many shares does Immatics have outstanding?
134,071,432 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-05.
Which country or territory is Immatics listed under?
Our directory records Immatics N.V. under Germany.
What does Immatics do?
Our directory classifies Immatics N.V. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Immatics?
The ISIN recorded for Immatics N.V. is NL0015285941.
Does aibio.space cover Immatics?
aibio.space lists Immatics N.V. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Immatics incorporated?
SEC records list its state or country of incorporation as P7.
What is the latest Immatics (IMTX) stock news?
Our latest story on Immatics, dated Aug 26, 2026: "Immatics agrees to sell shares and warrants at $8.69 in $150 million offering". Immatics agreed to sell 12,945,916 ordinary shares at $8.69, plus pre-funded warrants for 4,315,304 shares, for expected gross proceeds of $150 million. Its 2025 net loss was €196.4 million, after net income of €15.2 million in 2024. Source.
Is Immatics a smaller reporting company?
SEC records list Immatics N.V.'s filer category as: Accelerated filer.
Where is Immatics headquartered?
SEC records list its business address as PAUL EHRLICH-STRASSE 15, TUBINGEN, Germany, 72076.
When does Immatics's fiscal year end?
Immatics N.V.'s fiscal year ends on December 31, per SEC records.
What did Immatics last file with the SEC?
Its most recent filing in our record is a 6-K filed 2026-08-26. All of its filings are on SEC EDGAR. Source.
Investor discussion: Immatics
Members talk about Immatics (IMTX). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Immatics, newest first. Each line links the filing it comes from.
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:IMTX on TradingView.
SEC filings and registration
SEC name
Immatics N.V.
CIK
1809196
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
IMTX (Nasdaq)
State or country of incorporation
P7
Fiscal year ends
December 31
Filer category
Accelerated filer
Business address
PAUL EHRLICH-STRASSE 15, TUBINGEN, Germany, 72076
Phone
49 7071 5397 700
Shares outstanding
134,071,432 as of 2025-12-31 (20-F filed 2026-03-05)
Former names
Immatics B.V.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Immatics N.V. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IMTX, recorded under Germany. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio